Hans-Michael Kvasnicka

List of Publications by Year
in descending order

34	4,076	304368 22	433756 31
papers	citations	h-index	g-index

34	34	34	3113
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood, 2022, 140, 1200-1228.	0.6	814
2	Transglutaminase 2 promotes tumorigenicity of colon cancer cells by inactivation of the tumor suppressor p53. Oncogene, 2021, 40, 4352-4367.	2.6	17
3	Proteome activity landscapes of tumor cell lines determine drug responses. Nature Communications, 2020, 11, 3639.	5.8	47
4	Myeloproliferative Neoplasms. , 2020, , 146-161.		0
5	The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer Journal, 2018, 8, 15.	2.8	404
6	Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis. Journal of Hematology and Oncology, 2018, 11, 42.	6.9	63
7	Vemurafenib in Langerhans cell histiocytosis: report of a pediatric patient and review of the literature. Oncotarget, 2018, 9, 22236-22240.	0.8	34
8	Epstein-Barr virusâ€“specific cytokine-induced killer cells for treatment of Epstein-Barr virusâ€“related malignant lymphoma. Cytotherapy, 2018, 20, 839-850.	0.3	7
9	Increased tumor vascularization is associated with the amount of immune competent PDâ€1 positive cells in testicular germ cell tumors. Oncology Letters, 2018, 15, 9852-9860.	0.8	13
10	How to define treatment failure for JAK inhibitors. Lancet Haematology,the, 2017, 4, e305-e306.	2.2	9
11	European LeukemiaNet study on the reproducibility of bone marrow features in masked polycythemia vera and differentiation from essential thrombocythemia. American Journal of Hematology, 2017, 92, 1062-1067.	2.0	33
12	Dasatinib enhances tumor growth in gemcitabine-resistant orthotopic bladder cancer xenografts. BMC Research Notes, 2016, 9, 454.	0.6	2
13	Problems and pitfalls in grading of bone marrow fibrosis, collagen deposition and osteosclerosis â€“ a consensusâ€based study. Histopathology, 2016, 68, 905-915.	1.6	67
14	Differenzialdiagnose BCR-ABL1-negativer myeloproliferativer Neoplasien. Laboratoriums Medizin, 2015, 39, 301-310.	0.1	0
15	Microtubule-Depolymerizing Agents Used in Antibodyâ€“Drug Conjugates Induce Antitumor Immunity by Stimulation of Dendritic Cells. Cancer Immunology Research, 2014, 2, 741-755.	1.6	134
16	WHO Classification of Myeloproliferative Neoplasms (MPN): A Critical Update. Current Hematologic Malignancy Reports, 2013, 8, 333-341.	1.2	19
17	Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood, 2013, 121, 1720-1728.	0.6	281
18	Effects Of Five-Years Of Ruxolitinib Therapy On Bone Marrow Morphology In Patients With Myelofibrosis and Comparison With Best Available Therapy. Blood, 2013, 122, 4055-4055.	0.6	29

#	Article	IF	Citations
19	Effects Of Ruxolitinib Therapy On Megakaryocyte Morphology and Inflammatory Bone Marrow Reaction In Patients With Myelofibrosis. Blood, 2013, 122, 4056-4056.	0.6	5
20	European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. Haematologica 2012;97(3):360-5 - Comment. Haematologica, 2012, 97, e5-e6.	1.7	15
21	Decanucleotide Insertion Polymorphism of F7 Influences Significantly the Risk of Thrombosis in Patients with Essential Thrombocythemia. Blood, 2012, 120, 1730-1730.	0.6	0
22	Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification. Blood, 2011, 117, 5710-5718.	0.6	163
23	Prodromal myeloproliferative neoplasms: The 2008 WHO classification. American Journal of Hematology, 2010, 85, 62-69.	2.0	84
24	Bone Marrow Fibrosis and Diagnosis of Essential Thrombocythemia. Journal of Clinical Oncology, 2009, 27, e220-e221.	0.8	24
25	Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood, 2007, 110, 1092-1097.	0.6	808
26	Classification of Ph-Negative Chronic Myeloproliferative Disorders â€“ Morphology as the Yardstick of Classification. Pathobiology, 2007, 74, 63-71.	1.9	21
27	Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis. Experimental Hematology, 2007, 35, 1719-1722.	0.2	55
28	Clinicopathological Criteria for Differential Diagnosis of Thrombocythemias in Various Myeloproliferative Disorders. Seminars in Thrombosis and Hemostasis, 2006, 32, 219-230.	1.5	40
29	The Impact of Clinicopathological Studies on Staging and Survival in Essential Thrombocythemia, Chronic Idiopathic Myelofibrosis, and Polycythemia Rubra Vera. Seminars in Thrombosis and Hemostasis, 2006, 32, 362-371.	1.5	63
30	Initial (Latent) Polycythemia vera with Thrombocytosis Mimicking Essential Thrombocythemia. Acta Haematologica, 2005, 113, 213-219.	0.7	72
31	Bone Marrow Histopathology in Myeloproliferative Disordersâ€"Current Diagnostic Approach. Seminars in Hematology, 2005, 42, 184-195.	1.8	68
32	European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica, 2005, 90, 1128-32.	1.7	545
33	Follow-up examinations including sequential bone marrow biopsies in essential thrombocythemia (ET): A retrospective clinicopathological study of 120 patients. American Journal of Hematology, 2002, 70, 283-291.	2.0	50
34	Prognostic factors in idiopathic (Primary) osteomyelofibrosis. Cancer, 1997, 80, 708-719.	2.0	90